A post-marketing study evaluating the lipid-altering efficacy and safety of approved dose ranges of rosuvastatin in Indian hyperlipidemia patients in routine clinical practice (ROSUVEES)

This study demonstrated the efficacy and safety of rosuvastatin 5, 10 and 20 mg starting doses in improving lipid parameters and achieving lipid goals in a heterogeneous group of Indian hyperlipidemic patients in real life clinical practice. In patients with higher cardiovascular risk profile, rosuvastatin 10 and 20 mg are more effective starting doses for quicker achievement of NCEP-ATP III-defined lipid goals.